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Potential targetAbstract Orexin receptors belong to the big family of G protein coupled receptors (GPCRs) that
constitute the main targets in the modern pharmacological approaches. Although the orexinergic
system is involved in a variety of processes, treating sleep-wakefulness disorders such as narcolepsy
and insomnia, remains the main therapeutic implication of targeting orexinergic receptors. After
novel advances, such as the description of the binding pockets, and ligand developments, more
researchers are focusing on orexin receptors as promising targets. Furthermore, targeting these
receptors may provide therapeutic solutions for some health problems, other than sleep-wakefulness
disorders including some psychiatric disorders and neurodegenerative diseases. Within this paper,
we put a spotlight on the orexins’ physiology, pathophysiology and pharmacology of mainly
sleep-wakefulness. We have also reviewed examples about other orexinergic system-related disor-
ders. We further illustrated recent development in orexin receptors’ agonists and antagonists.
In addition, we discussed selected progresses in orexinergic receptors’ ligands.
ª 2014 Alexandria University Faculty of Medicine. Production and hosting by Elsevier B.V. All rights
reserved.
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system has been shown, or hypothesized, to play roles.
Mechanisms/eﬀects References
Regulation of appetite and stress response 24–26
Respiratory eﬀects 27–29
Addiction 11,25,26,30–38
Behavioral changes associated
with cocaine administration
39
Analgesia 11,40
Food intake regulation 23,41
Central regulation of feeding (of blind caveﬁsh) 42
Regulation of glucose metabolism 43,44
Energy balance regulation 45,46
Insulin secretion regulation 44
Variability in diet-induced obesity sensitivity 47
Proliferation and viability of 3T3-L1 preadipocytes 48
Body temperature regulation 46,49
Neuroendocrine function 6,49,50
Pituitary hormone secretion 51
Cardiovascular activities 49,52–54
Post-ischemic attenuation of inﬂammatory responses
(neuroprotection)
55
Prevention of cerebral ischemic neuronal
damage (neuroprotection)
43
Reproduction 56–62
Motor activity 50,54
Migraine 63
Arousal states 45,64,65
Narcolepsy and cataplexy 45,64–68
Major depression 69
Epileptic activity 401. Introduction
Among the emerging targets in neuropharmacology, orexin
receptors are objects of more focus. A food intake study had
led, in 1998, to the discovery of neurotransmitter orexins
(OX), also called hypocretins (hcrt), in the rat lateral hypotha-
lamic area (LHA).1,2 The hypothalamic neuropeptides orexin-
A and orexin-B interact with two orphan GPCRs.3 Indeed,
orexinergic receptors (OXR) type 1 and type 2 (OX1R and
OX2R) are G-protein-coupled receptors (GPCRs).1,2,4 Orex-
in-B has been pointed as showing 10–100-fold higher potency
at the OX2 receptor than at the OX1 receptor2,5, whereas
OX-A binds with similar afﬁnity to both receptors.4 It has also
been reported that during proestrous afternoon there is an
increased expression of OX1R and OX2R,6 and, in sleep, the
secretion of orexin is seasonally dependent,7 which shows a
time-dependant activity of the orexinergic system. Studies on
the intracellular pathways and signal transductions have
shown that Ox/hcrt-R1 is coupled to Gq-type G protein,
whereas ox/hcrt-R2 is coupled to both Gi/o and Gq proteins.8
GPCRs are receptors that are characterized by the factors that
can inﬂuence their activity9 and the signal transduction signal
they implicate.10 Regarding the corresponding intracellular
downstream, orexin G protein-coupled receptors couple to
different proteins including phospholipases and kinases.11,12
The cellular and molecular bases of the orexinergic system’s
functions lie on both the orexinergic receptors and the corre-
sponding pathway that involves diverse intracellular mecha-
nisms such as the inhibition of the cyclic AMP(cAMP)
synthesis.13 Orexins and their receptors have been described
both inside and outside the brain, for instance, the presence
of both receptors in the ovary was demonstrated.6
Within this mini-review, we describe, via illustrative
examples, some of the possible therapeutical applications and
pharmacological properties that have been linked to the orex-
inergic system. Although treatment of sleep-wakefulness disor-
ders, like insomnia,14 remains the main pharmacological
application, other therapeutical implications seem interesting.
2. Physiological and pathophysiological overview of the
orexinergic system
Orexin system (ox/hcrt system) has been described in several
physiological and pathophysiological processes, mainly in the
regulation of sleep and wakefulness.15–20 Indeed, the ventrolat-
eral preoptic nucleus (VLPO) is suggested to send inhibitory
signals to both orexin neurons and the ‘‘arousal center’’,
whereas orexin neurons depolarize the ‘‘arousal center’’ duringthe wake stage.21,22 Other functions and properties, among
which selected examples are summarized in Table 1, have also
been linked to the orexinergic system. Furthermore, since
peripheral organs have been shown to involve orexins, we
suggest that orexins play other roles in more physiological
functions23 which suppose novel possibilities for the related
pharmacotherapies.
3. Pharmacology and potential therapeutics
Orexinergic system-related pharmacological and therapeutic
researches have recently started to overcome the struggle of
the lack of developed synthetic antagonists.70 However, the
majority of those synthetic antagonists are not commercially
available.71 Agonist and antagonist binding pockets of orexin
receptors are gradually being unveiled, therefore, we expect
more advances in ligand researches.72 Sleep-wakefulness
Targeting the orexinergic system 281remains the main topic among orexin system-related
researches. In fact, selective activation of ox/hcrt-R2 promotes
wakefulness.73 In addition, whereas orexin neuron inactivation
was linked with sleep, their activation promotes the wakeful-
ness.74,75 Therefore, pharmaceutical companies are aiming to
develop agents that would target the Hcrt system in vivo70 as
new therapies, not only for sleep disorders, but also for other
diseases and disorders.76 Such advances highlight the progress
of the pharmaceutical industry in the pharmacological target-
ing of the orexinergic system. For example, orexin receptors’
blocking could constitute a treatment for insomnia.77 Follow-
ing this idea, Johnson & Johnson has pointed that blockade of
OX1R can reduce OX2R antagonist-induced sleep promotion
in rats.78 More importantly, due to insomnia statistics and the
pathologies that have been linked to this disorder, we realize
that developing treatment for insomnia will constitute an
important advancement in neuropsychiatry. Insomnia is a
common neuropsychiatric disorder with a chronic form that
affects 20% of the adult population.79 Importantly, insomnia
has been linked to depression, obesity, cardiovascular disease,
cancer and chronic pain.80–84 Moreover, insomnia may lead to
depression85 and sleep disturbances are frequently observed in
multiple sclerosis (MS) patients.86 Studies of diverse new
agents and receptors have reported numerous compounds
and targets for developing novel insomnia treatments, among
them we mention central nervous system (CNS) histamine
receptors, GABA(A), melatonin and serotonin modulators.87
However, sedative-hypnotics that target GABA receptors rep-
resent the main current therapy for insomnia.18 Starting from
the hypothesis that the new compounds that are potentially
effective in various types of insomnia, which is associated with
some disease, can, via the alleviation of insomnia, directly
result in the improvement of those diseases, we suppose that
treating insomnia using novel approaches might have three
main consequences: {1} Reduce the incidence of the above
mentioned disorders,1{2}improve the prognosis of insomnia-
related pathologies and {3} provide an alternative to the agents
that target GABA receptors and thus, avoid the side effects of
such class of drugs (see: Fig. 1).
In mammals, the hypothalamus is the unique brain region
orexin neurons are restricted to49,50,88–90, but brain anatomy
shows an important distribution of orexin neurons49,89,91,
and many brain regions, in addition to other extra cerebral
structures, have orexin neuron ﬁbers including the medianNew neuropsychiatric
pharmacotherapy
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Figure 1 Some possible consequences ofeminence, arcuate nucleus, pituitary, olfactory bulb, cerebral
cortex, thalamus subfornical organ, area postrema, hippocam-
pus, amygdala, indusium griseum, brainstem and spinal
cord49,89,91–94, thus pharmacological beneﬁts of targeting orex-
inergic neurons might be extended into those structures in the
future.
Orexinergic neurons, that form a unique central orexinergic
system,50 project to regions associated with different cerebral
functions such as reward, learning and memory, emotion
and attention,49 supposing a possible modiﬁcation of these
functions by orexin receptors’ ligands, either as an eventual
therapeutical approach or as a side effect of orexin receptors’
ligands. Importantly, interactions of the orexinergic system
with other neurotransmitters have also been reported. For
instance, in anesthetized rats, the activation of orexin neurons
can be obtained via a local disinhibition of neurons of perifor-
nical region95 of the posterior hypothalamus neurons by
GABA (A) receptor antagonists.53 Interestedly, the implica-
tion of orexin A and orexin B in the regulation of monoamin-
ergic and cholinergic neuron function in wakefulness
maintenance has also been reported.3 Furthermore, orexin
application to the rat brain produces serotonergic and
cholinergic neuron depolarization,96,97 and orexin has been
shown to modify the synaptic activity of dopamine neurons.30
Moreover, a recent publication has shown that the increase of
glutamatergic synaptic transmission in the ventral tegmental
area (VTA) has been linked to OX2R activity.30 Finally,
whereas OxA/hcrt-1N-methyl-D aspartate receptor
(NMDAR)-mediated synaptic transmission of dopamine neu-
rons in the VTA has also been reported,95,98–102 intra-VTA
administration of oxA/hcrt-1 results in an increased local
dopamine and glutamate release.103,104 These interactions
between the orexinergic system and other neurotransmitters
could be exploited either to a better understanding of the orex-
inergic system underlying pathways or to develop more selec-
tive drugs. At the same time such interactions can lead to
complex side effects of the orexinergic receptors’ ligands.
Based on the orexin related-pharmacological properties,
pharmaceutical companies are trying to develop drugs that tar-
get orexin receptors, mainly to treat sleep disorders.3 It was
reported that small molecule orexin receptor antagonists can
help patients suffering from insomnia by promoting sleep.105
Herein, we state some orexin receptors’ ligands that have been
either pointed in clinical trials or that may be effective forl 
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282 A. Ghanemi, X. Huinsomnia treatment. SB-334867 constituted the most often
used orexinergic antagonist in the literature.106 Whereas SB-
649868 constitutes an emerging antagonist in development by
GlaxoSmithKline,107 a new selective and highly potent spiropi-
peridine-based OX2R antagonist was discovered in 2011.77 On
the other hand, several papers have pointed to the two orexin
receptor antagonists: suvorexant and almorexant (or ACT-
078573), these small molecules have, in addition to their ability
to promote sleep in animals, clinical efﬁcacy.19,108 Further-
more, for the treatment of primary insomnia, the phase III
of clinical trials of suvorexant has been completed.3 Previously
suvorexant, considered as the most advanced dual orexin
receptor antagonist (DORA),76 was reported to induce sleep
in humans109 with analogous potency toward both OX1R
and OX2R.108,110 Among suvorexant, MK-6096 (a piperidi-
no-derived) and DORA-22 that are dual orexin receptor
antagonists (DORAs),18 MK-6096 and DORA-22 show a high
selectivity for OX1R and OX2R therefore, have the pharmaco-
logical properties to decrease wakefulness and thus, represent
potential agents for sleep/wake dysregulation treatment.18
Previously, eszopiclone (ESZ), a cyclopyrrolone targeting
GABA-A receptor111,112, was pointed to suppress orexinergic
neurons’ activity with a possible use in insomnia treat-
ment.113-117 This datum gets its importance from the fact that
many hypnotic agents target GABA-A receptor,118,119 which
strengthens the theory that links orexin system to insomnia.
Another class of orexin 2 antagonists, that includes 2-
methyl-3-furanyl-4H-1,2,4-triazol-3-ylthioamides, has been
described as well.120 Pharmacokinetics described different
routes of administration of orexin receptors’ antagonists.
For instance, almorexant can be administered orally, while
SB-334867 can be injected systemically121, thus gives a
clinical use ﬂexibility of such drugs.
Since orexin receptors are subject to active drug develop-
ment, more advances are emerging and many orexin receptors
antagonists are mentioned in the literature.105,120 Whereas, in
2007, GlaxoSmithKline brought out data about an orexin
receptor antagonist for the clinical treatment of insomnia,70
the two dual OX1R/OX2R receptor antagonists: almorexant
and MK-4305 were entered in Phase-III, but almorexant was
discontinued.77 Herein, we mention that pharmacokinetic
interaction of almorexant with both simvastatin and atorva-
statin has been recently reported.122 It has been reported that
orexin receptors’ non-subtype-selective antagonists may pro-
vide agents with hypnotic properties as well.70 Importantly,
it has been shown that intraperitoneal injection of OX1R
antagonist can inhibit OXA-triggered food intake, feeding
behavior and weight gain.123,124 In addition, the study of the
role of oxA/hcrt-1 in addiction-associated behaviors might
help to develop agents for the treatment of pathological
stress-related behaviors.30 Researches have also given indica-
tions about the impact of the molecular structure and receptor
type on the drug activity. Indeed, D-Leu15-orexin-B (A11,
DL15-orexin-B) may be more selective for OX2 receptors com-
pared to OX1 receptors.125 In addition, factors including
expression level, coupling efﬁciency and signal pathways have
been linked to agonist potency126 thus, taking into account
such data will be a good contribution to drug design especially
of chemical-derived drugs.
Genetic therapy has also found its place among the
orexin-related therapies. Indeed, a recent study pointed that
it is possible to both control cataplexy attacks and modestlyimprove wake maintenance by orexin gene transfer into the
dorsolateral pontine neurons.127 Finally, animal experiments
contribute strongly in the evaluation of potential orexin recep-
tor ligands. For instance, orexin-2 receptor antagonist TCS-
OX2-29 was reported to induce a decreased wakefulness in
rats.20 In addition, the organization of the hypothalamus orex-
inergic system has been studied in both giraffe (Giraffa camel-
opardalis) and harbor porpoise (Phocoena phocoena), which
belong to the mammalian order128, thus allow a better
understanding of the human orexinergic system and provide
important orientations for future trials.4. Perspectives
In summary, we highlight the main pharmacological properties
of orexin receptors’ ligands: Antagonists have hypnotic prop-
erties and offer a new approach to insomnia treatment,129
while agonists may have beneﬁts for hypersomnia and narco-
lepsy.130 Because of some struggles, such as the non-commer-
cial availability of most of the developed antagonists,71
targeting orexin receptors still constitutes a new area of
research. Importantly, several papers have highlighted the pos-
sible therapeutic usages of orexin receptors’ ligands in a variety
of other cerebral and neurological disorders including the use
of orexin receptor antagonist as cognitive enhancer in post-
traumatic stress disorder (PTSD),77 eating disorder,131,132
Alzheimer’s disease (via reducing amyloid-b),133 panic
anxiety134 and addiction.135,136 In addition, as orexin (hypocre-
tin) has been linked to both nicotine withdrawal (130) and
addiction,137,138 it was supposed that further investigations
on this property may lead to develop agents that can help
smoking cessation.139 Moreover, in tetrahydrocannabinol
(THC) as well as nicotine dependence, the orexinergic system
constitutes a potential target,137 which may give more impor-
tance to this emerging aspect of cerebral pharmacology. More-
over, whereas in some clinical anxiety disorders, characterized
by intense emotional arousal, orexin receptor antagonists
might turn out to be a therapy,140 the orexin receptor antago-
nist (MK-6096) has been reported as a potential treatment of
chronic migraine.141 Importantly, pharmacological blockade
of the orexinergic system leads to an antidepressant-like
effect.69 The studied chemical properties of the potential
OXR ligands may provide a starting point to future drug
development through compound screening say for example.
In addition, molecules, such as some laboratory reagents and
solvents, that have been reported to have biological or
pharmacological effects on GPCRs,142,143 could constitute
candidates in drug design or experimental developments in
orexinergic system-related researches. All these pharmacologi-
cal and clinical data point out clearly how this new area is
underestimated, thus further investigations are strongly recom-
mended especially within the context that could clearly clarify
the toxicology and pharmacology of the drugs144,145 that may
be provided by natural products146,147
In contrast, orexinergic neuron distribution and the interac-
tions of the orexinergic system with other neurotransmitters
might result in inﬂuences of orexin receptors’ ligands on differ-
ent physiological and pathophysiological mechanisms, mainly
those in which orexin system is implicated. Especially if we
consider the cerebral neuro-system as a complex network
within which different neurotransmitters are in continuous
Targeting the orexinergic system 283interactions.148,149 Therefore, a particular pharmacovigilance
for agents targeting the orexinergic system remains highly
important.
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